Liquidia reports Q1 EPS (54c), consensus (32c)

Reports Q1 revenue $2.97M, consensus $4.39M. Cash and cash equivalents totaled $157.9M as of March 31, compared to $83.7M as of December 31, 2023. Roger Jeffs, Liquidia’s CEO, said: “We continue to vigorously pursue final agency action for YUTREPIA’s approval for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). And as we have shown, we will remain relentless in the defense of our freedom to go to market despite the myriad of legal filings by our competitor. At our core is our steadfast commitment to deliver YUTREPIA to patients with PAH and PH-ILD. We feel YUTREPIA can provide an important and differentiated alternative to address lingering unmet needs that continue to limit the optimal delivery of inhaled treprostinil.”